Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease

被引:0
作者
Santiago Perez-Lloret
Olivier Rascol
机构
[1] University of Buenos Aires,Institute of Cardiology Research
[2] National Research Council (CONICET-ININCA),Department of Clinical Pharmacology and Neurosciences and NeuroToul Center of Excellence in Neurodegeneration (COEN)
[3] University Hospital and University of Toulouse III,NS
[4] INSERM CIC1436 and UMR1214,Park/FCRIN Network
[5] INSERM,undefined
来源
CNS Drugs | 2016年 / 30卷
关键词
Levodopa; Bromocriptine; Parkinson Disease; Dopamine Agonist; Pramipexole;
D O I
暂无
中图分类号
学科分类号
摘要
Dopamine agonists are well-established symptomatic medications for treating early and advanced Parkinson disease (PD). Piribedil was one of the first agonists to be marketed (1969) and is widely used as an extended-release oral formulation in European, Latin-American, and Asian countries. Piribedil acts as a non-ergot partial dopamine D2/D3-selective agonist, blocks alpha2-adrenoreceptors and has minimal effects on serotoninergic, cholinergic, and histaminergic receptors. Animal models support the efficacy of piribedil to improve parkinsonian motor symptoms with a lower propensity than levodopa to induce dyskinesia. In PD patients, randomized double-blind studies show that piribedil (150–300 mg/day, three times daily) is superior to placebo in improving motor disability in early PD patients. Based on such evidence, piribedil was considered in the last Movement Disorder Society Evidence-Based Medicine review as “efficacious” and “clinically useful” for the symptomatic treatment of PD, either as monotherapy or in conjunction with levodopa, in non-fluctuating early PD patients. This effect appears comparable to what is known from other D2 agonists. However, randomized controlled trials are not available to assess the effect of piribedil in managing levodopa-induced motor complications. Pilot clinical studies suggest that piribedil may improve non-motor symptoms, such as apathy, but confirmatory trials are needed. The tolerability and safety profile of piribedil fits with that of the class of dopaminergic agonists. As for other non-ergot agonists, pneumo-pulmonary, retroperitoneal, and valvular fibrotic side effects are not a concern with piribedil. The original combination of piribedil D2 dopaminergic and alpha-2 adrenergic properties deserve further investigations to better understand its antiparkinsonian profile.
引用
收藏
页码:703 / 717
页数:14
相关论文
共 234 条
[1]  
Pringsheim T(2014)The prevalence of Parkinson’s disease: a systematic review and meta-analysis Mov Disord 29 1583-1590
[2]  
Jette N(1992)Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatry 55 181-184
[3]  
Frolkis A(1998)Parkinson’s disease. First of two parts N Engl J Med 339 1044-1053
[4]  
Hughes AJ(2009)Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment Lancet Neurol 8 464-474
[5]  
Daniel SE(2015)The concept of prodromal Parkinson’s disease J Parkinsons Dis 5 681-697
[6]  
Kilford L(1998)The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism Parkinsonism Relat Disord 4 59-60
[7]  
Lang AE(2007)Levodopa-induced dyskinesias Mov Disord 22 1379-1389
[8]  
Lozano AM(2001)Motor fluctuations and dyskinesia in Parkinson’s disease Parkinsonism Relat Disord 8 101-108
[9]  
Chaudhuri KR(2010)Dopamine receptor agonists for the treatment of early or advanced Parkinson’s disease CNS Drugs 24 941-968
[10]  
Schapira AH(2007)Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease Lancet Neurol 6 826-829